e-learning
resources
Virtual 2020
Wednesday, 09.09.2020
Severe asthma phenotypes and outcomes
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma
K. Eger (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands)
Source:
Virtual Congress 2020 – Severe asthma phenotypes and outcomes
Session:
Severe asthma phenotypes and outcomes
Session type:
Oral Presentation
Number:
5041
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Eger (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands). Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma. 5041
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study
Source: International Congress 2017 – Monitoring asthma control
Year: 2017
Real life benralizumab effect in patients with severe eosinophilic asthma after 16 weeks of observation
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
Source: Eur Respir J 2013; 42: 1224-1233
Year: 2013
Inflammatory biomarkers in the evaluation of two-year outcomes of omalizumab treatment in severe allergic asthma.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Real prevalence of severe asthma in developing countries – Is the diagnosis correct?
Source: Virtual Congress 2020 – Clinical parameters in severe asthma
Year: 2020
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Predicting treatment outcomes following an exacerbation of airways disease
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
The course of disease of patients who died from asthma and COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 217s
Year: 2003
Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Severe asthma outcomes over 18-months treatment with mepolizumab, and comorbidities in non-responders.
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Predictors of asthma progressive course in patients with autoimmune thyroiditis
Source: Eur Respir J 2007; 30: Suppl. 51, 554s
Year: 2007
Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations
Source: Eur Respir J 2007; 30: Suppl. 51, 72s
Year: 2007
Severe asthma outcomes over two years of therapy with mepolizumab
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept